Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $39.08 USD
Change Today +0.71 / 1.85%
Volume 315.8K
CMRX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

chimerix inc (CMRX) Snapshot

Open
$38.76
Previous Close
$38.37
Day High
$39.65
Day Low
$38.61
52 Week High
02/23/15 - $43.41
52 Week Low
05/20/14 - $14.02
Market Cap
1.6B
Average Volume 10 Days
345.9K
EPS TTM
$-1.77
Shares Outstanding
41.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHIMERIX INC (CMRX)

chimerix inc (CMRX) Related Businessweek News

View More BusinessWeek News

chimerix inc (CMRX) Details

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds include brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, as well as to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections. Its preclinical testing product includes CMX669 for the treatment of BK virus and CMV. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for certain antiviral indications; and BARDA to develop brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

76 Employees
Last Reported Date: 03/6/15
Founded in 2000

chimerix inc (CMRX) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $340.0K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2013.

chimerix inc (CMRX) Key Developments

Chimerix, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Chimerix, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $1,156,000 against $879,000 a year ago. Loss from operations was $20,226,000 against $7,979,000 a year ago. Net loss attributable to common stockholders was $20,247,000 against $8,174,000 a year ago. Net loss, basic and diluted share was $0.52 against $0.31 a year ago. The variance in loss from operations is due primarily to the increase in research and development and general and administrative expenses. The increase in revenues is primarily due to an increase in the fourth quarter of 2014 in reimbursable expenses associated with its ongoing contract with BARDA. The variance in loss from operations was due primarily to an increase in research and development expenses and general and administrative expenses. For the year, the company reported total revenues of $4,040,000 against $4,370,000 a year ago. Loss from operations was $58,866,000 against $28,619,000 a year ago. Net loss attributable to common stockholders was $59,312,000 against $70,533,000 a year ago. Net loss, basic and diluted share was $1.80 against $3.65 a year ago. The variance in loss from operations is due primarily to the increase in research and development and general and administrative expenses.

Chimerix, Inc. to Report Q4, 2014 Results on Mar 06, 2015

Chimerix, Inc. announced that they will report Q4, 2014 results at 8:30 AM, US Eastern Standard Time on Mar 06, 2015

Chimerix, Inc., Q4 2014 Earnings Call, Mar 06, 2015

Chimerix, Inc., Q4 2014 Earnings Call, Mar 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMRX:US $39.08 USD +0.71

CMRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr336.50 DKK -2.00
Bioporto A/S kr1.73 DKK +0.02
Emergent Biosolutions Inc $29.97 USD +0.14
GlaxoSmithKline PLC 1,575 GBp -6.00
Novartis AG SFr.99.20 CHF +1.50
View Industry Companies
 

Industry Analysis

CMRX

Industry Average

Valuation CMRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 371.6x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 331.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHIMERIX INC, please visit www.chimerix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.